Qiagen (NYSE:QGEN) Stock Position Cut by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its stake in shares of Qiagen (NYSE:QGEN) by 70.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 126,059 shares of the company’s stock after selling 304,687 shares during the period. Janus Henderson Group PLC owned approximately 0.06% of Qiagen worth $5,696,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in QGEN. Massmutual Trust Co. FSB ADV boosted its holdings in shares of Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after buying an additional 243 shares during the period. CWM LLC boosted its holdings in shares of Qiagen by 12.0% during the second quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after purchasing an additional 269 shares during the period. Atria Investments Inc boosted its stake in shares of Qiagen by 6.0% during the 3rd quarter. Atria Investments Inc now owns 7,632 shares of the company’s stock valued at $348,000 after buying an additional 433 shares during the period. Private Advisor Group LLC grew its stake in Qiagen by 8.0% in the third quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock valued at $285,000 after purchasing an additional 461 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after buying an additional 500 shares in the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Price Performance

QGEN stock opened at $44.33 on Tuesday. The stock has a 50-day moving average price of $43.07 and a two-hundred day moving average price of $43.65. Qiagen has a 1 year low of $39.03 and a 1 year high of $47.44. The stock has a market cap of $10.12 billion, a PE ratio of 113.67, a price-to-earnings-growth ratio of 3.37 and a beta of 0.35. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39.

Analysts Set New Price Targets

Several equities analysts have weighed in on QGEN shares. Hsbc Global Res upgraded Qiagen to a “hold” rating in a report on Thursday, October 17th. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Four research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $50.80.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.